Bioorthogonal Click of Colloidal Gold Nanoparticles to Antibodies In vivo. Issue 61 (1st September 2022)

• Record Type: Journal Article
• Authors: Poulie, Christian B. M.; Sporer, Emanuel; Hvass, Lars; Jørgensen, Jesper T.; Kempen, Paul J.; Lopes van den Broek, Sara I.; Shalgunov, Vladimir; Kjaer, Andreas; Jensen, Andreas I.; Herth, Matthias M.
• Is Part Of: Chemistry. Volume 28:Issue 61(2022)
• Page Start: n/a
• Page End: n/a
• Publication Date: 2022-09-01
• Subjects: bioorthogonal chemistry -- click chemistry -- gold nanoparticles -- pretargeting -- tetrazine ligation; Chemistry -- Periodicals; 540
• DOI: 10.1002/chem.202201847
• Languages: English
• ISSNs: 0947-6539

Abstract

Abstract: Combining nanotechnology and bioorthogonal chemistry for theranostic strategies offers the possibility to develop next generation nanomedicines. These materials are thought to increase therapeutic outcome and improve current cancer management. Due to their size, nanomedicines target tumors passively. Thus, they can be used for drug delivery purposes. Bioorthogonal chemistry allows for a pretargeting approach. Higher target‐to‐background drug accumulation ratios can be achieved. Pretargeting can also be used to induce internalization processes or trigger controlled drug release. Colloidal gold nanoparticles (AuNPs) have attracted widespread interest as drug delivery vectors within the last decades. Here, we demonstrate for the first time the possibility to successfully ligate AuNPs in vivo to pretargeted monoclonal antibodies. We believe that this possibility will facilitate the development of AuNPs for clinical use and ultimately, improve state‐of‐the‐art patient care. Abstract : Combining nanotechnology and bioorthogonal chemistry. Due to their size, nanomedicines target tumors passively. Whereas bioorthogonal chemistry allows for a pretargeting approach. Herein, we demonstrate ‐ for the first time ‐ the possibility to successfully ligate Tz‐AuNPs in vivo to pretargeted monoclonal antibodies.